News

Company News & Events

ORYZON Announces Exercise of Warrants by Alzheimer’s Drug Discovery Foundation (ADDF)

7 November 2016

BARCELONA, SPAIN and CAMBRIDGE MA.

• A new step in the collaboration to fight Alzheimer’s Disease

Oryzon Genomics (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that the Alzheimer’s Drug Discovery Foundation (ADDF) exercised warrants and lending rights over 175,071 ordinary shares of the Company, at an exercise price of EUR 3.43 per share (par value EUR 0.05 each) representing 0.6% of the capital.

Click here to see the full Press Release

Posted In: 
Investors
News

Share this story